Name | Number of supported studies | Average coverage | |
---|---|---|---|
enterocyte | 6 studies | 35% ± 5% |
Insufficient scRNA-seq data for expression of ACE2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 97% | 1638.40 | 86 / 89 | 75% | 10.38 | 680 / 901 |
intestine | 51% | 1773.61 | 497 / 966 | 58% | 3.21 | 305 / 527 |
pancreas | 72% | 247.96 | 237 / 328 | 37% | 1.52 | 65 / 178 |
heart | 99% | 1286.56 | 854 / 861 | 0% | 0 | 0 / 0 |
thymus | 92% | 834.81 | 601 / 653 | 2% | 0.03 | 10 / 605 |
esophagus | 59% | 182.22 | 850 / 1445 | 22% | 0.82 | 40 / 183 |
adipose | 80% | 1006.72 | 969 / 1204 | 0% | 0 | 0 / 0 |
breast | 72% | 728.88 | 331 / 459 | 3% | 0.13 | 28 / 1118 |
stomach | 14% | 43.38 | 52 / 359 | 55% | 3.66 | 158 / 286 |
lung | 40% | 116.28 | 233 / 578 | 16% | 0.58 | 181 / 1155 |
liver | 36% | 82.88 | 82 / 226 | 16% | 0.68 | 65 / 406 |
ovary | 52% | 308.81 | 93 / 180 | 0% | 0.00 | 1 / 430 |
bladder | 19% | 25.29 | 4 / 21 | 21% | 1.10 | 104 / 504 |
adrenal gland | 28% | 49.15 | 71 / 258 | 8% | 4.38 | 19 / 230 |
uterus | 23% | 62.74 | 39 / 170 | 8% | 0.19 | 36 / 459 |
muscle | 20% | 53.91 | 163 / 803 | 0% | 0 | 0 / 0 |
prostate | 20% | 50.80 | 48 / 245 | 0% | 0.00 | 1 / 502 |
blood vessel | 19% | 91.84 | 252 / 1335 | 0% | 0 | 0 / 0 |
skin | 6% | 11.85 | 116 / 1809 | 1% | 0.01 | 3 / 472 |
tonsil | 0% | 0 | 0 / 0 | 4% | 0.05 | 2 / 45 |
brain | 1% | 2.22 | 24 / 2642 | 0% | 0 | 0 / 705 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_2000272 | Biological process | negative regulation of signaling receptor activity |
GO_0019229 | Biological process | regulation of vasoconstriction |
GO_0003081 | Biological process | regulation of systemic arterial blood pressure by renin-angiotensin |
GO_0061025 | Biological process | membrane fusion |
GO_0070373 | Biological process | negative regulation of ERK1 and ERK2 cascade |
GO_0060452 | Biological process | positive regulation of cardiac muscle contraction |
GO_0098670 | Biological process | entry receptor-mediated virion attachment to host cell |
GO_0050727 | Biological process | regulation of inflammatory response |
GO_0097746 | Biological process | blood vessel diameter maintenance |
GO_0046813 | Biological process | receptor-mediated virion attachment to host cell |
GO_0051957 | Biological process | positive regulation of amino acid transport |
GO_1903598 | Biological process | positive regulation of gap junction assembly |
GO_0046718 | Biological process | symbiont entry into host cell |
GO_0002003 | Biological process | angiotensin maturation |
GO_2000379 | Biological process | positive regulation of reactive oxygen species metabolic process |
GO_0048662 | Biological process | negative regulation of smooth muscle cell proliferation |
GO_0019065 | Biological process | receptor-mediated endocytosis of virus by host cell |
GO_0001817 | Biological process | regulation of cytokine production |
GO_0019058 | Biological process | viral life cycle |
GO_0003051 | Biological process | angiotensin-mediated drinking behavior |
GO_1903779 | Biological process | regulation of cardiac conduction |
GO_1905737 | Biological process | positive regulation of L-proline import across plasma membrane |
GO_0022898 | Biological process | regulation of transmembrane transporter activity |
GO_0015827 | Biological process | tryptophan transport |
GO_0042127 | Biological process | regulation of cell population proliferation |
GO_0060135 | Biological process | maternal process involved in female pregnancy |
GO_0031526 | Cellular component | brush border membrane |
GO_0016324 | Cellular component | apical plasma membrane |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0045121 | Cellular component | membrane raft |
GO_0016020 | Cellular component | membrane |
GO_0030666 | Cellular component | endocytic vesicle membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0009986 | Cellular component | cell surface |
GO_0005788 | Cellular component | endoplasmic reticulum lumen |
GO_0005929 | Cellular component | cilium |
GO_0008241 | Molecular function | peptidyl-dipeptidase activity |
GO_0004175 | Molecular function | endopeptidase activity |
GO_0008237 | Molecular function | metallopeptidase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0001618 | Molecular function | virus receptor activity |
GO_0004181 | Molecular function | metallocarboxypeptidase activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0004180 | Molecular function | carboxypeptidase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | ACE2 |
Protein name | Angiotensin-converting enzyme (EC 3.4.-.-) Angiotensin-converting enzyme 2 (EC 3.4.17.23) (Angiotensin-converting enzyme homolog) (ACEH) (Angiotensin-converting enzyme-related carboxypeptidase) (ACE-related carboxypeptidase) (EC 3.4.17.-) (Metalloprotease MPROT15) [Cleaved into: Processed angiotensin-converting enzyme 2] Angiotensin converting enzyme 2 |
Synonyms | UNQ868/PRO1885 |
Description | FUNCTION: Essential counter-regulatory carboxypeptidase of the renin-angiotensin hormone system that is a critical regulator of blood volume, systemic vascular resistance, and thus cardiovascular homeostasis . Converts angiotensin I to angiotensin 1-9, a nine-amino acid peptide with anti-hypertrophic effects in cardiomyocytes, and angiotensin II to angiotensin 1-7, which then acts as a beneficial vasodilator and anti-proliferation agent, counterbalancing the actions of the vasoconstrictor angiotensin II . Also removes the C-terminal residue from three other vasoactive peptides, neurotensin, kinetensin, and des-Arg bradykinin, but is not active on bradykinin . Also cleaves other biological peptides, such as apelins (apelin-13, [Pyr1]apelin-13, apelin-17, apelin-36), casomorphins (beta-casomorphin-7, neocasomorphin) and dynorphin A with high efficiency . In addition, ACE2 C-terminus is homologous to collectrin and is responsible for the trafficking of the neutral amino acid transporter SL6A19 to the plasma membrane of gut epithelial cells via direct interaction, regulating its expression on the cell surface and its catalytic activity . .; FUNCTION: (Microbial infection) Acts as a receptor for human coronaviruses SARS-CoV and SARS-CoV-2, as well as human coronavirus NL63/HCoV-NL63. .; FUNCTION: [Isoform 2]: Non-functional as a carboxypeptidase. .; FUNCTION: [Isoform 2]: (Microbial infection) Non-functional as a receptor for human coronavirus SARS-CoV-2. . |
Accessions | ENST00000678046.1 A0A8S0M502 A0A7I2V4H0 ENST00000679278.1 A0A7I2V2E9 ENST00000680121.1 [Q9BYF1-1] A0A7I2V3N4 ENST00000679212.1 ENST00000427411.2 [Q9BYF1-1] ENST00000678073.1 [Q9BYF1-1] Q9BYF1 ENST00000252519.8 [Q9BYF1-1] A0A7I2V3X6 ENST00000471548.5 ENST00000679162.1 ENST00000677282.1 [Q9BYF1-3] A0A7I2V5W5 |